Squamous Overgrowth Is Not a Safety Concern for Photodynamic Therapy for Barrett's Esophagus With High-Grade Dysplasia

Gastroenterology

Volumn 136, Issue 1, 2009, Pages 56-64

  Bronner, Mary P ^a   Overholt, Bergein F ^b   Taylor, Shari L ^c   Haggitt, Rodger C ^d   Wang, Kenneth K ^e   Burdick, J Steven ^f   Lightdale, Charles J ^g   Kimmey, Michael ^d   Nava, Hector R ^h   Sivak, Michael V ⁱ   Nishioka, Norman ^j   Barr, Hugh ^k   Canto, Marcia I ^l   Marcon, Norman ^m   Pedrosa, Marcos ⁿ   Grace, Michael ^o   Depot, Michelle ^p  

^a LERNER RESEARCH INSTITUTE   (United States)

^b THOMPSON CANCER SURVIVAL CENTER   (United States)

^c CARIS LIFE SCIENCES   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e MAYO CLINIC   (United States)

^f PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^g New York Presbyterian Hospital Columbia University Medical Center   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^l JOHNS HOPKINS HOSPITAL   (United States)

^m ST MICHAEL'S HOSPITAL   (Canada)

ⁿ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^o UNIVERSITY OF ALBERTA   (Canada)

^p Axcan Pharma Inc   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PHOTOFRIN; PHOTOFRIN II;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPLASIA; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL; TREATMENT FAILURE; AGED; BIOPSY; ESOPHAGUS; MIDDLE AGED; PATHOLOGY; PHOTOCHEMOTHERAPY;

AGED; BARRETT ESOPHAGUS; BIOPSY; DIHEMATOPORPHYRIN ETHER; ESOPHAGUS; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PHOTOCHEMOTHERAPY;

EID: 59849089442     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.10.012     Document Type: Article

References (37)

1. Barrett N.R. Chronic peptic ulcer of the oesophagus and oesophagitis. Br J Surg 38 (1950) 175-182
2. Allison P.R., and Johnstone A.S. The oesophagus lined with gastric mucous membrane. Thorax 8 (1953) 87-101
3. Reid B.J. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin of North Am 20 (1991) 817-834
4. Stein H.J., and Siewart J.R. Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration and surgical management. Dysphagia 8 (1993) 276-288
5. Haggitt R.C. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25 (1994) 982-993
6. Haggitt R.C., Tryzellar J., Ellis F.H., et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 70 (1978) 1-5
7. Weston A.P., Sharma P., Topalovski M., et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 95 (2000) 1888-1893
8. Schnell T.G., Sontag S.J., Cheifec G., et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120 (2001) 1607-1619
9. Reid B.J., Levine D.S., Longton G., et al. Prediction of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95 (2000) 1669-1676
10. Montgomery E., Goldblum J.R., Greenson J.K., et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32 (2001) 379-388
11. Ell C., May A., Gossner L., et al. Endoscopic mucosal resection of early cancer and high grade dysplasia in Barrett's esophagus. Gastroenterology 118 (2000) 670-677
12. Soehendra N., Seewald S., Groth S., et al. Use of modified multiband ligator facilitates circumferential endoscopic mucosal resection in Barrett's esophagus. (with video). Gastrointest Endosc 63 (2006) 847-852
13. Gossner L., Stolte M., Sroka R., et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 114 (1998) 448-455
14. Barr H., Shepherd N.A., Dix A., et al. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 348 (1996) 584-585
15. Wang K.K. Photodynamic therapy of Barrett's esophagus. Gastrointest Endosc Clin N Am 10 (2000) 409-419
16. Wolfsen H.C., Hemminger L.L., Wallace M.B., et al. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmocol Ther 20 (2004) 1125-1131
17. Overholt B.F., Panjehpour M., and Halberg D.L. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long term results. Gastrointest Endosc 58 (2003) 183-188
18. Overholt B.F., Lightdale C.J., Wang K.K., et al. International photodynamic group for high-grade dysplasia in Barrett's esophagus. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62 (2005) 488-498
19. Overholt B.F., Wang K.K., Burdick J.S., et al., International photodynamic group for high-grade dysplasia in Barrett's esophagus. Five-year efficacy and safety of photodynamic therapy with photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 66 (2007) 460-468
20. Smith C.D., Bejarano P.A., Melvin W.S., et al. Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system. Surg Endosc 21 (2007) 560-569
21. Ganz R.A., Overholt B.F., Sharma V.K., et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc 68 (2008) 35-40
22. Gossner L., May A., Stolte M., et al. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endosc 49 (1999) 8-12
23. Byrne J.P., Armstrong G.R., and Attwood S.E. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 93 (1998) 1810-1815
24. Attwood S.E., Lewis C.J., Caplin S., et al. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol 1 (2003) 258-263
25. Hage M., Siersema P.D., van Dekken H., et al. 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's esophagus: a randomized trial. Gut 53 (2004) 785-790
26. Johnston M.H., Eastone J.A., Horwhat J.D., et al. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc 62 (2005) 842-848
27. Pacifico R.J., Wang K.K., Wongkeesong L.M., et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 1 (2003) 252-257
28. Buttar N.S., Wang K.K., Lutzke L.S., et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 54 (2001) 682-688
29. Van Laetham J.L., Pepy M.O., Salmon I., et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's esophagus. Gut 46 (2000) 574-577
30. Ban S., Mino M., Nishioka N.S., et al. Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett's esophagus. Am J Surg Pathol 28 (2004) 1466-1473
31. Mino-Kenudson M., Ban S., Obana M., et al. Buried dysplasia and early adenocarcinoma arising in Barrett esophagus after porfimer-photodynamic therapy. Am J Pathol 31 (2007) 403-409
32. Montgomery E., Bronner M.P., Goldblum J.R., et al. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum Pathol 32 (2001) 368-378
33. Sharma P., Sampliner R.E., and Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy dose not result in regression of Barrett's esophagus. Am J Gastroenterol 92 (1997) 582-585
34. Wilkinson S.P., Biddlestone L., Gore S., et al. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 13 (1999) 1205-1209
35. Amano Y., Kushiyama Y., Yuki T., et al. Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy. J Gastroenterol Hepatol 22 (2007) 901-907
36. Hornick J.L., Mino-Kenudson M., Lauwers G.Y., et al. Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. Am J Gastroenterol 103 (2008) 38-47
37. Krishnadath K.K., Wang K.K., Taniguchi K., et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 119 (2000) 624-630